Chardan Capital Reaffirms “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “buy” rating reissued by investment analysts at Chardan Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $26.00 target price on the stock. Chardan Capital’s target price would suggest a potential upside of 201.97% from the stock’s previous close.

Several other equities research analysts have also weighed in on FDMT. Barclays assumed coverage on 4D Molecular Therapeutics in a report on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 price objective for the company. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 7th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.71.

4D Molecular Therapeutics Trading Down 4.1%

Shares of NASDAQ FDMT opened at $8.61 on Thursday. The stock has a fifty day simple moving average of $8.75 and a two-hundred day simple moving average of $9.10. 4D Molecular Therapeutics has a 1-year low of $2.23 and a 1-year high of $12.34. The firm has a market cap of $439.54 million, a price-to-earnings ratio of -3.56 and a beta of 2.99.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative return on equity of 31.75% and a negative net margin of 164.43%.The firm had revenue of $85.09 million for the quarter, compared to analyst estimates of $30.86 million. Analysts forecast that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in FDMT. AQR Capital Management LLC bought a new stake in shares of 4D Molecular Therapeutics during the first quarter valued at about $46,000. Millennium Management LLC boosted its position in shares of 4D Molecular Therapeutics by 15.0% in the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock valued at $5,278,000 after acquiring an additional 213,264 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in 4D Molecular Therapeutics during the first quarter valued at approximately $39,000. American Century Companies Inc. grew its stake in 4D Molecular Therapeutics by 11.5% during the second quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock valued at $181,000 after acquiring an additional 5,026 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in 4D Molecular Therapeutics during the 2nd quarter worth approximately $292,000. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics News Summary

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: High-profile firms reiterated bullish views and raised targets, supporting upside potential — HC Wainwright reaffirmed a “buy” and set a $36 target (very large implied upside). Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $35 and gave an “outperform” rating, signaling strong analyst conviction on mid/long-term value. Read More.
• Positive Sentiment: Chardan Capital reaffirmed a “buy” with a $26 target, adding another supportive research note. Read More.
• Positive Sentiment: Fundamental beat: 4D reported Q4 EPS of $0.43 (well ahead of consensus) and revenue of $85.1M, which typically supports higher valuations and reduces near-term execution risk. Read More.
• Neutral Sentiment: Analyst commentary is mixed across the sector; some aggregation pieces note divergent views on FDMT which can increase intraday volatility without clear directional pressure. Read More.
• Neutral Sentiment: Short-interest reports in the latest feeds show anomalous/zero values (reports indicate increases but list 0 shares/NaN), suggesting the data feed is unreliable — this appears to be noise rather than a clear short-squeeze or large shorting event.
• Negative Sentiment: Cantor Fitzgerald issued a “hold” on FDMT, which can dampen momentum from the bullish notes and makes the street’s view less one-sided. Read More.
• Negative Sentiment: New risk disclosure: a TipRanks piece highlights reimbursement and pricing pressures that could materially affect the commercial outlook for FDMT’s gene therapies — a real demand/price-risk that can weigh on valuation and near-term sentiment. Read More.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.